Effect of early artificial tear administration on dry eye symptoms following phacoemulsification cataract surgery Artykuł oryginalny
##plugins.themes.bootstrap3.article.main##
Abstrakt
Methods: This prospective, single-blind, interventional parallel-group study included 32 eyes of 32 patients undergoing phacoemulsification cataract surgery. Patients were randomly allocated into two groups: one group received artificial tears (AT) starting the day after surgery (AT group, n = 16), while the other did not receive artificial tears (No AT group, n = 16). Schirmer I test (without anaesthesia) was used to evaluate dry eye, and the OSDI questionnaire was used preoperatively and at 1 and 3 weeks postoperatively. Statistical analysis was conducted using Mann–Whitney test, paired t-test, Cochran’s Q test, and Fisher’s Exact test, with p <0.05 considered statistically significant.
Results: Baseline demographics characteristics, BCVA, and preoperative OSDI scores were comparable between groups. At week 1 postoperatively, dry eye incidence was higher in the No AT group (68.7%) compared with the AT group (37.5%), though this difference was not statistically significant (p = 0.077). At week 3, the AT group demonstrated a significantly lower incidence of dry eye (12.5%) compared with the No AT group (50.0%) (OR = 0.14, p = 0.036). Within- group analysis showed a significant improvement in Schirmer test results over time in the AT group (p = 0.041), but not in the No AT group (p = 0.091). Postoperative OSDI scores exhibited a significant decline across both groups; however, the AT group demonstrated a markedly superior reduction at week 1 (p = 0.018) and week 3 (p = 0.0003) follow-up intervals.
Conclusion: Early postoperative administration of artificial tears significantly reduces dry eye incidence and symptoms severity following cataract surgery. Artificial tears appear to facilitate faster ocular surface recovery and improve patient-reported outcomes without affecting visual acuity. Incorporating artificial tears into routine postoperative care may enhance comfort and quality of life in patients undergoing cataract surgery.
##plugins.generic.usageStats.downloads##
##plugins.themes.bootstrap3.article.details##

Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
2. Priyadarshini K, Sharma N, Kaur M et al. Cataract surgery in ocular surface disease. Indian J Ophthalmol. 2023; 71(4): 1167-75. http://doi.org/10.4103/IJO.IJO_3395_22.
3. Cicinelli M, Buchan J, Nicholson M et al. Cataracts. Lancet. 2022; 401, 377-89.
4. Lu Q, Lu Y, Zhu X. Dry Eye and Phacoemulsification Cataract Surgery: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021; 8: 649030. http://doi.org/10.3389/fmed.2021.649030.
5. Lee CY, Yang SF, Chen HC et al. The Mid-Term Effect of Preservative-Free Artificial Tears Containing Hyaluronic Acid on Dry Eye Incidence after Cataract Surgery: A Retrospective Cohort Study. Diagnostics (Basel). 2024; 14(17): 1848. http://doi.org/10.3390/diagnostics14171848.
6. Miura M, Inomata T, Nakamura M et al. Prevalence and Characteristics of Dry Eye Disease After Cataract Surgery: A Systematic Review and Meta-Analysis. Ophthalmol Ther. 2022; 11(4): 1309-32. http://doi.org/10.1007/s40123-022-00513-y.
7. Nuzzi A, Tibaldi D, Nuzzi R. The impact of cataract surgery on tear film physiology: signs and symptoms, progression and treatment. Front Med (Lausanne). 2025; 12: 1559323. http://doi.org/10.3389/fmed.2025.1559323.
8. Rossi GCM, Tinelli C, Milano G et al. Randomised, Single Blind, Controlled, Three-Month Clinical Trial on the Evaluation and Treatment of the Ocular Surface Damage Following Phacoemulsification. Vision (Basel). 2022; 6(3): 42. http://doi.org/10.3390/vision6030042.
9. Bharucha K, Zanzarukiya J, Hegade A et al. A comparative study to evaluate the effect of various postoperative treatment protocols on dry eye and patient satisfaction after phacoemulsification. Indian J Ophthalmol. 2023; 71(4): 1638-42. http://doi.org/10.4103/IJO.IJO_2775_22.
10. Miklaszewski P, Gadamer AM, Janiszewska-Bil D et al. Comparison of Postoperative Outcomes in 71 Patients Undergoing Cataract Surgery at a Single Center with and Without Preoperative Keratostill Moisturizing Eye Drops. J Clin Med. 2025; 14(12): 4349. http://doi.org/10.3390/jcm14124349.
11. Anwar A, Mumtaz Chaudhry M, Samra A et al. Changes in Tear Film and Ocular Surface after Phacoemulsification for Senile Cataract. Pakistan Journal of Medical Health Sciences. 2023; 16(12): 759. http://doi.org/10.53350/pjmhs20221612759.
12. Jensen P, Nilsen C, Gundersen M et al. A Preservative-Free Approach - Effects on Dry Eye Signs and Symptoms After Cataract Surgery. Clin Ophthalmol. 2024; 18: 591-604. http://doi.org/10.2147/OPTH.S446804.
13. Sidaraite A, Mikalauskiene L, Grzybowski A et al. Evaluation of Ocular Surface after Cataract Surgery-A Prospective Study. J Clin Med. 2022; 11(15): 4562. http://doi.org/10.3390/jcm11154562.
14. Mencucci R, Favuzza E, Decandia G et al. Hyaluronic Acid/Trehalose Ophthalmic Solution in Reducing Post-Cataract Surgery Dry Eye Signs and Symptoms: A Prospective, Interventional, Randomized, Open-Label Study. J Clin Med. 2021; 10(20): 4699. http://doi.org/10.3390/jcm10204699.
15. Labetoulle M, Benitez-Del-Castillo JM, Barabino S et al. Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease. Int J Mol Sci. 2022; 23(5): 2434. http://doi.org/10.3390/ijms23052434.
16. Favuzza E, Cennamo M, Vicchio L et al. Protecting the Ocular Surface in Cataract Surgery: The Efficacy of the Perioperative Use of a Hydroxypropyl Guar and Hyaluronic Acid Ophthalmic Solution. Clin Ophthalmol. 2020; 14: 1769-75. http://doi.org/10.2147/OPTH.S259704.